Ποια είναι η τιμή για Beta Bionics, Inc. (BBNX)

Η τιμή για Beta Bionics, Inc. (BBNX) είναι $19.81

Ποια είναι η κεφαλαιοποίηση αγοράς για Beta Bionics, Inc. (BBNX)

Η κεφαλαιοποίηση αγοράς για Beta Bionics, Inc. (BBNX) είναι $891.32M

Beta Bionics, Inc. (BBNX) Τιμή και Κεφαλαιοποίηση Αγοράς

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

Η τιμή για BBNX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$117,002 $891.32M	NVDA	$5.264T	+590,468.44%
$104,497 $891.32M	AAPL	$4.701T	+527,349.64%
$92,847.45 $891.32M	GOOG	$4.177T	+468,549.57%
$84,850.58 $891.32M	MSFT	$3.817T	+428,185.19%
$63,710.97 $891.32M	AMZN	$2.866T	+321,482.56%

Η τιμή για BBNX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$117,002 $891.32M